RNF113A and small cell lung carcinoma: However, cisplatin is generally mislabeled as an alkylating agent, and we found that cisplatin does not directly activate RNF113A E3 ligase activity in SCLC and that SMYD3–RNF113A signaling does not affect SCLC cell sensitivity to cisplatin.